Cargando…
Selective targeting of metastatic ovarian cancer using an engineered anthrax prodrug activated by membrane-anchored serine proteases
Treatments for advanced and recurrent ovarian cancer remain a challenge due to a lack of potent, selective, and effective therapeutics. Here, we developed the basis for a transformative anticancer strategy based on anthrax toxin that has been engineered to be selectively activated by the catalytic p...
Autores principales: | Duru, Nadire, Pawar, Nisha R., Martin, Erik W., Buzza, Marguerite S., Conway, Gregory D., Lapidus, Rena G., Liu, Shihui, Reader, Jocelyn, Rao, Gautam G., Roque, Dana M., Leppla, Stephen H., Antalis, Toni M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282395/ https://www.ncbi.nlm.nih.gov/pubmed/35867758 http://dx.doi.org/10.1073/pnas.2201423119 |
Ejemplares similares
-
Targeting the membrane-anchored serine protease testisin with a novel engineered anthrax toxin prodrug to kill tumor cells and reduce tumor burden
por: Martin, Erik W., et al.
Publicado: (2015) -
Intersection of Coagulation and Fibrinolysis by the Glycosylphosphatidylinositol (GPI)-Anchored Serine Protease Testisin
por: Buzza, Marguerite S., et al.
Publicado: (2023) -
Fibrinolysis and Inflammation in Venous Thrombus Resolution
por: Mukhopadhyay, Subhradip, et al.
Publicado: (2019) -
Membrane-Anchored Serine Proteases in Health and Disease
por: Antalis, Toni M., et al.
Publicado: (2011) -
Extracellular: Plasma Membrane Proteases – Serine Proteases
por: Antalis, T.M., et al.
Publicado: (2016)